ArticleJournal of inflammation research2026
Serum Cytokine Profiles in Patients with Inflammatory Bowel Disease in Clinical Remission: A Cross-Sectional Comparison by Anti-TNF Therapy.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Inflammatory bowel diseases (IBDs) are a group of idiopathic diseases that include Crohn's disease (CD) and ulcerative colitis (UC). According to the Global Burden of Diseases, Injuries, and Risk Factors Study, 6.8 million people lived with IBD in 2017. Monitoring cytokine levels can provide information about the effectiveness of therapy and help adjust treatment to achieve better clinical outcomes. This cross-sectional study aimed to assess whether serum cytokine profiles differ between patients receiving anti-TNF therapy and those not receiving biologic treatment in a cohort restricted to clinical remission, and to evaluate their potential clinical utility. Methods: The study included 132 IBD patients who were in remission of the disease and 29 control subjects. Cytokine levels (GM-CSF, INFγ, IL13, IL1β, IL4, IL23, IL6, TNFα) were measured and compared between patients receiving biologic therapy and those not receiving biologic treatment. Results: No significant differences were observed in the concentrations of the cytokines studied between the individual groups of patients receiving anti-TNF therapy and those receiving conventional therapy. Overall, cytokine profiles showed limited discriminatory value in patients in clinical remission. Conclusion: Regardless of the treatment method used (conventional vs. biologic therapy), no differences were observed in the profiles of pro-inflammatory and anti-inflammatory cytokines among patients in clinical remission. These results suggest that blood levels of TNF-α and other cytokines do not depend solely on anti-TNF therapy, indicating the need for longitudinal studies to assess their potential role in predicting relapse or loss of response to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.